|
Status |
Public on Apr 25, 2014 |
Title |
Regulation of gene expressions in vivo by anti-VEGF and anti-Notch therapy [HG-U133_Plus_2] |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
U87-EV human glioblastoma xenograft tumours is therapeutically treated by bevacizumab, a humanized anti-human VEGF mAb, or dibenzazepine (DBZ), when tumour is established in BALB/c SCID mice. At the end point, collect tumour samples and extracted total RNA for microarray to investigate the gene profile changes compared to control. These include the genes from human tumour cells and mouse host stroma cells.
|
|
|
Overall design |
3 control samples, 3 dibenzazepine-treated samples, 3 bevacizumab-treated samples
|
|
|
Contributor(s) |
Buffa F, Harris A |
Citation(s) |
23871637 |
|
Submission date |
Jul 10, 2012 |
Last update date |
Mar 25, 2019 |
Contact name |
Francesca Buffa |
E-mail(s) |
[email protected]
|
Organization name |
University of Oxford
|
Street address |
The Weatherall Institute of Molecular Medicine
|
City |
Oxford |
ZIP/Postal code |
OX3 9DS |
Country |
United Kingdom |
|
|
Platforms (1) |
GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
Samples (9)
|
GSM958322 |
U87-EV human glioblastoma xenograft - Control - 1 [HG-U133_Plus_2] |
GSM958323 |
U87-EV human glioblastoma xenograft - Control - 2 [HG-U133_Plus_2] |
GSM958324 |
U87-EV human glioblastoma xenograft - Control - 3 [HG-U133_Plus_2] |
GSM958325 |
U87-EV human glioblastoma xenograft - dibenzazepine treated - 1 [HG-U133_Plus_2] |
GSM958326 |
U87-EV human glioblastoma xenograft - dibenzazepine treated - 2 [HG-U133_Plus_2] |
GSM958327 |
U87-EV human glioblastoma xenograft - dibenzazepine treated - 3 [HG-U133_Plus_2] |
GSM958328 |
U87-EV human glioblastoma xenograft - Bevacizumab treated - 1 [HG-U133_Plus_2] |
GSM958329 |
U87-EV human glioblastoma xenograft - Bevacizumab treated - 2 [HG-U133_Plus_2] |
GSM958330 |
U87-EV human glioblastoma xenograft - Bevacizumab treated - 3 [HG-U133_Plus_2] |
|
Relations |
BioProject |
PRJNA170248 |